BioMerieux has announced the appointment of Nicolas Cartier as the new corporate vice-president of its industrial microbiology unit and a member of its management committee.
Mr Cartier joins the company after spending most of his career with pharmaceutical company Sanofi, where he served in a number of key roles, including most recently that of general manager of Sanofi France.
He will be tasked with piloting BioMerieux's ambitious growth strategy in industrial microbiology, which is seen as a promising field for specialisation.
The firm offers the largest microbiological control product range on the market, with more than 200 employees involved in the development of the business unit.
Jean-Luc Belingard, chairman and chief executive officer of BioMerieux, said: "His international experience and his knowledge of the pharmaceutical sector will represent valuable assets, enabling BioMerieux to meet the current challenges our customers have to face."
This week, the company also announced that it has received US regulatory approval for the new molecular test THxID-BRAF, for use in the assessment of melanoma sufferers.See all the latest jobs in Science